Applying ctDNA and Other Liquid Biopsy Technologies for Oncology Translational and Clinical Research
Brian Dougherty, Director, Translational Genomics, AstraZeneca Oncology
For over seven years, AstraZeneca’s Translational Science Oncology
group has applied NGS technologies to patient testing, particularly in
the liquid biopsy space. Discussion of our experiences will include: - Opportunities and challenges in ctDNA testing for mutational profiling, patient selection, and patient monitoring
- Orthogonal bench-marking study of commercial ctDNA assays
- One
finding: in current testing, most tumor-plasma discordance is due to
assay technical performance, not tumor heterogeneity or clonal
hematopoesis
- Landscape of the exosomal transcriptome and some potential implications for use for cancer patient testing
- Single cell DNA and RNA technologies
- Testing of patient samples from hematological cancers by single cell sequencing
|
|
Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
